PD-L1

Zapraszamy do zapoznania się z archiwalnymi szkoleniami online dotyczącymi diagnostyki genetycznej z użyciem kompleksu PD-L1. 


Tytuł

Data

Prelegent

The Rationale Behind the Scoring Systems for PD-L1 IHC to Determine Patients Eligible for KEYTRUDA® (pembrolizumab)

18 września 2019

Dr. Kristopher Kersch, MD, Pathologist,
Agilent Technologies

The Value of Companion Diagnostic (CDx) IHC Assays in the Complex Environment of PD-L1 Testing

28 maja 2019

Dr. Allen Gown, BS (SUNY-Stony Brook), MD (Albert Einstein College of Medicine)
Founder and Senior Pathologist, PhenoPath Laboratories;
Clinical Professor, Dept. of Pathology, University of British Columbia

The Value of Participation in a PD-L1 EQA Program / PD-L1 Implementation in EQA Programs

26 października 2017

Professor Mogens Vyberg,
University Hospital Aalborg, Denmark, and
Andreas Scheel, MD,
University Hospital Cologne, Germany

Introduction to PD-L1 Interpretation in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

17 pażdziernika 2017

Annika Eklund, PhD, and
Debra Hanks, MD,
Agilent Technologies, Inc.

Advanced PD-L1 Interpretation

27 wrzesnia 2017

Professor Hans-Ulrich Schildhaus,
University Medical Center,
Göttingen, Germany

Basic Interpretation of PD-L1 Expression

1 czerwca 2017

Professor Bharat Jasani,
Targos Molecular Pathology GmbH,
Kassel, Germany

How to Easily and Simply Implement PD-L1 Testing in Your Lab - Verification / Validation

20 kwietnia 2017

Carol Cheung, MD, PhD, JD,
University Health Network,
University of Toronto, Canada

A Blueprint for PD-L1 Testing - Development and Value of the PD-L1 22C3 Assay

6 kwietnia 2017

Kenneth J. Bloom,
Head of Oncology and Immunotherapy,
Human Longevity, Inc., San Diego, USA

 

Szukaj w serwisie